Anne-sophie S. Alary

Marseille, France

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 24 publications

Relationship Between Salvage Strategy and Outcomes in Patients With CBF or NPM1-mutated AML and First Molecular Relapse.

Relationship Between Salvage Strategy and Outcomes in Patients With CBF or NPM1-mutated AML and First Molecular Relapse.

Journal: Blood advances

Published: May 13, 2026

The contribution of high-throughput sequencing in malignant hematological disorders

The contribution of high-throughput sequencing in malignant hematological disorders

Journal: La Revue du praticien

Published: June 23, 2025

Implementation science in hemato-oncology molecular diagnostics in France via the Groupe des Biologistes Moléculaire des Hémopathies Malignes (GBMHM).

Implementation science in hemato-oncology molecular diagnostics in France via the Groupe des Biologistes Moléculaire des Hémopathies Malignes (GBMHM).

Journal: HemaSphere

Published: March 05, 2025

Efficacy and safety of azacitidine for VEXAS syndrome: a large-scale retrospective study from FRENVEX.

Efficacy and safety of azacitidine for VEXAS syndrome: a large-scale retrospective study from FRENVEX.

Journal: Blood

Published: February 11, 2025

Asciminib resistance of a new BCR::ABL1 p.I293_K294insSSLRD mutant detected in a Ph + ALL patient.

Asciminib resistance of a new BCR::ABL1 p.I293_K294insSSLRD mutant detected in a Ph + ALL patient.

Journal: Annals of hematology

Published: May 02, 2024

Venetoclax-based non-intensive induction followed by allogenic stem-cell transplantation in elderly acute myeloid leukemia patients with adverse cytogenetics.

Venetoclax-based non-intensive induction followed by allogenic stem-cell transplantation in elderly acute myeloid leukemia patients with adverse cytogenetics.

Journal: European journal of haematology

Published: April 03, 2024

Poor prognosis of SRSF2 gene mutations in patients treated with VEN-AZA for newly diagnosed acute myeloid leukemia.

Poor prognosis of SRSF2 gene mutations in patients treated with VEN-AZA for newly diagnosed acute myeloid leukemia.

Journal: Leukemia research

Published: March 04, 2024

Long-term survival of NPM1 AML treated with intensive chemotherapy with extensive molecular data available.

Long-term survival of NPM1 AML treated with intensive chemotherapy with extensive molecular data available.

Journal: Leukemia & lymphoma

Published: February 08, 2024

Very short insertions in the FLT3 gene are of therapeutic significance in acute myeloid leukemia.

Very short insertions in the FLT3 gene are of therapeutic significance in acute myeloid leukemia.

Journal: Blood advances

Published: October 12, 2023

Azacitidine-venetoclax versus azacitidine salvage treatment for primary induction failure or first relapsed acute myeloid leukaemia patients.

Azacitidine-venetoclax versus azacitidine salvage treatment for primary induction failure or first relapsed acute myeloid leukaemia patients.

Journal: European journal of haematology

Published: August 03, 2023

Targeted High-throughput Sequencing for Hematological Malignancies: A GBMHM Survey of Practice and Cost Evaluation in France.

Targeted High-throughput Sequencing for Hematological Malignancies: A GBMHM Survey of Practice and Cost Evaluation in France.

Journal: HemaSphere

Published: April 19, 2023

Azacitidine Plus Venetoclax for the Treatment of Relapsed and Newly Diagnosed Acute Myeloid Leukemia Patients.

Azacitidine Plus Venetoclax for the Treatment of Relapsed and Newly Diagnosed Acute Myeloid Leukemia Patients.

Journal: Cancers

Published: March 08, 2022

Showing 1-12 of 24

Last Updated: 09/26/2026